News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
XenoPort, Inc. Says U.S. FDA Won’t Require Advisory Panel
January 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Xenoport Inc. said U.S. regulators won’t require an advisory panel to review the company’s application for an experimental drug to ease restless legs syndrome.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Vaccines
HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space
April 29, 2025
·
2 min read
·
Tristan Manalac
Earnings
Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far
April 24, 2025
·
3 min read
·
Annalee Armstrong
Vaccines
After Missed Decision Deadline, Novavax Says COVID-19 Shot ‘Approvable’
April 24, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ for Delaying Stomach Drug
April 24, 2025
·
2 min read
·
Tristan Manalac